Dihydro-5-azacytidine (DHAC), the nucleoside analog, is incorporated into DNA and inhibits DNA methylation . Dihydro-5-azacytidine has an antitumor activity.

Methylation studies show that an LD 10 dose of [3H]DHAC results in a 25.06% hypomethylation of DNA in L1210/0 cells and a 46.32% hypomethylation in a deoxycytidine kinase mutant cell line L1210/dCK(-), compared with their respective controls[2]. Dihydro-5-azacytidine (DHAC) competes with cytidine triphosphate for incorporation into RNA, leading to ribosomal degradation and defective protein synthesis[1].

In tumor-bearing mice (injected with L1210/0 cells), after an LD 10 dose of Dihydro-5-azacytidine (DHAC; 1500 mg/kg), the plasma peak concentration achieved is 317 μM and is eliminated biexponentially, with a t 1/2 α of 1.03 h and a t 1/2 β of 5 h[2].

62488-57-7

C8H14N4O5

246.22

Dihydro-5-azacytidine;NSC264880;DHAC;Dihydro-5-azacytidine

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years